Main Industry
Biotechnology
Main Product/Service
1. Antibodies and Reagents
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort™
7. Non-Human Primate Antibodies
8. Recombinant Proteins, C
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort™
7. Non-Human Primate Antibodies
8. Recombinant Proteins, C
The content above was translated by Ai
Founded Year
2010
Unified Business No.
53138320
Status
Active
Number of Employees
0
Total Paid-in
Capital
100,000,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
The content above was translated by Ai
